Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
- DOI
- 10.1053/j.gastro.2023.08.038
- Published
- 2023 Dec
- Container
- Gastroenterology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1053/j.gastro.2023.08.038,
title = {Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.},
author = {Peyrin-Biroulet L and Allegretti JR and Rubin DT and Bressler B and Germinaro M and Huang KG and Shipitofsky N and Zhang H and Wilson R and Han C and Feagan BG and Sandborn WJ and Panés J and Hisamatsu T and Lichtenstein GR and Sands BE and Dignass A and QUASAR Study Group},
year = {2023},
journal = {Gastroenterology},
doi = {10.1053/j.gastro.2023.08.038},
url = {https://doi.org/10.1053/j.gastro.2023.08.038}
}RIS
TY - JOUR TI - Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. AU - Peyrin-Biroulet L AU - Allegretti JR AU - Rubin DT AU - Bressler B AU - Germinaro M AU - Huang KG AU - Shipitofsky N AU - Zhang H AU - Wilson R AU - Han C AU - Feagan BG AU - Sandborn WJ AU - Panés J AU - Hisamatsu T AU - Lichtenstein GR AU - Sands BE AU - Dignass A AU - QUASAR Study Group PY - 2023 JO - Gastroenterology DO - 10.1053/j.gastro.2023.08.038 UR - https://doi.org/10.1053/j.gastro.2023.08.038 ER -
APA
L, P., JR, A., DT, R., B, B., M, G., KG, H., N, S., H, Z., R, W., C, H., BG, F., WJ, S., J, P., T, H., GR, L., BE, S., A, D., & Group, Q. S. (2023). Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.. Gastroenterology. https://doi.org/10.1053/j.gastro.2023.08.038
Source records
- pubmed · retrieved 2026-09-26T02:40:39.749Z